| Human epidermal growth factor receptor-2 and hormonal therapies: clinical implications. | |
| | |
MedLine Citation:
|
PMID: 12756077 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Estrogen-targeted therapies such as administration of tamoxifen or aromatase inhibitors are among the most important treatment strategies in the modern management of breast cancer. Despite initial responses in the metastatic setting and prolonged disease-free intervals in the adjuvant setting, many patients subsequently become resistant to these agents. Human epidermal growth factor receptor-2 (HER2) is a transmembrane glycoprotein receptor that is overexpressed in 13%-30% of human breast cancers. There are experimental data suggesting an important role for HER2 in de novo and acquired resistance to endocrine therapies. These experimental data are discussed in this article, as are clinical data addressing the role of HER2 in resistance to endocrine therapy in the adjuvant, neoadjuvant, and metastatic settings. Responses and benefit from tamoxifen appear to be impaired in patients in whom HER2 is overexpressed. In contrast, early data from the neoadjuvant setting suggest that responses to aromatase inhibitors may be maintained in patients with HER2 overexpression. |
| | |
Authors:
|
Alistair Ring; Mitch Dowsett |
Related Documents
:
|
12867067 - Integration of the proteasome inhibitor ps-341 (velcade) into the therapeutic approach ... 9703907 - Keratinocyte growth factor (kgf) induces aromatase activity in cultured mcf-7 human bre... 21547577 - Gene copy number variation in male breast cancer by acgh. 18254777 - Egfr expression in urothelial carcinoma of the upper urinary tract is associated with d... 11091657 - Biological effects of heavy ion beam on human breast cancers. 8739077 - Regularity and length of menstrual cycles in women aged 41-46 in relation to breast can... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Clinical breast cancer Volume: 4 Suppl 1 ISSN: 1526-8209 ISO Abbreviation: Clin. Breast Cancer Publication Date: 2003 Apr |
Date Detail:
|
Created Date: 2003-05-20 Completed Date: 2005-11-22 Revised Date: 2009-11-19 |
Medline Journal Info:
|
Nlm Unique ID: 100898731 Medline TA: Clin Breast Cancer Country: United States |
Other Details:
|
Languages: eng Pagination: S34-41 Citation Subset: IM |
Affiliation:
|
Department of Academic Biochemistry, Wallace Wing, Royal Marsden Hospital, London, United Kingdom. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents, Hormonal
/
pharmacology*,
therapeutic use Aromatase Inhibitors / pharmacology*, therapeutic use Breast Neoplasms / drug therapy*, metabolism Chemotherapy, Adjuvant Drug Resistance, Neoplasm / drug effects Female Humans Neoadjuvant Therapy Randomized Controlled Trials as Topic Receptor, Epidermal Growth Factor / drug effects, metabolism* Receptor, erbB-2 / drug effects, metabolism* Receptors, Estrogen / drug effects Survival Analysis Tamoxifen / pharmacology*, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents, Hormonal; 0/Aromatase Inhibitors; 0/Receptors, Estrogen; 10540-29-1/Tamoxifen; EC 2.7.10.1/Receptor, Epidermal Growth Factor; EC 2.7.10.1/Receptor, erbB-2 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast canc...
Next Document: Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial.